Becton, Dickinson (BDX) said Wednesday it completed enrollment in a trial evaluating Phasix Mesh for preventing incisional hernias.
The company said the study enrolled 477 patients across 32 sites in the US and Europe and will evaluate the use of resorbable mesh to prevent incisional hernias.
Patients will be followed through the trial's primary endpoint at 24 months, with longer-term follow-up planned for five years, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.